Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRG-002 in Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events
NCT07503028Phase 1Enrolling by invitation
- Sponsor
- Celregen Therapeutics
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CRG-002 in type 1 diabetes mellitus (T1D) and pancreatogenic diabetes mellitus (T3cDM), sponsored by Celregen Therapeutics. Primary endpoint: Number of adverse events according to CTCAE v 6.0 at 1 year. Started Oct 2025; status: enrolling by invitation.
02
Drugs
CRG-002
03
Conditions
type 1 diabetes mellitus (T1D)pancreatogenic diabetes mellitus (T3cDM)
Beyond the preview
Go deeper on NCT07503028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503028.